Lung Cancer Clinical Trial
Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients
Summary
This study aims to establish a tolerable dose level and regimen of RAD001 in combination with cisplatin and etoposide (standard-of-care chemotherapy) in patients with extensive stage small-cell lung cancer (SCLC) who have not previously been treated with systemic chemotherapy.
Eligibility Criteria
Inclusion criteria:
Patients with histologically or cytologically confirmed diagnosis of extensive disease small-cell lung cancer (ED SCLC)
Age ≥ 18 years
WHO Performance Status Grade ≤ 1 (ie. ability to perform normal daily functions)
Adequate bone marrow, liver and renal function
Exclusion criteria:
Chronic steroid treatment
Prior treatment with chemotherapy for advanced lung cancer
Prior treatment with mTOR inhibitors
Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers, eye conditions, chronic liver or kidney disorders, uncontrolled diabetes, infections or other severe medical conditions
Symptomatic or uncontrolled brain metastases
Other cancers within the past 5 years
Pregnant or breastfeeding women
Other protocol-defined inclusion/exclusion criteria may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Fayetteville Arkansas, 72703, United States
Aurora Colorado, 80045, United States
Boston Massachusetts, 02115, United States
Houston Texas, 77030, United States
San Antonio Texas, 78229, United States
Paris , , France
How clear is this clinincal trial information?